Integral Derivatives’s GSK GSK Stock Holding History

Integral Derivatives’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-6,539	Closed	-$349K	–	1164
2017 Q1	$345K	Sell	6,539 -13,695	-68%	-$695K	0.01%	852
2016 Q4	$974K	Buy	+20,234	New	+$1,000K	0.02%	519
2016 Q3	–	Sell	-4,375	Closed	-$240K	–	1051
2016 Q2	$237K	Buy	+4,375	New	+$230K	0.01%	799
2015 Q4	–	Sell	-6,055	Closed	-$309K	–	1124
2015 Q3	$291K	Buy	6,055 +2,160	+55%	+$112K	0.01%	866
2015 Q2	$203K	Buy	+3,895	New	+$219K	0.01%	981
2015 Q1	–	Sell	-4,455	Closed	-$238K	–	1207
2014 Q4	$238K	Buy	+4,455	New	+$249K	﹤0.01%	1171
2014 Q1	–	Sell	-25,175	Closed	-$1.68M	–	1420
2013 Q4	$1.68M	Buy	+25,175	New	+$1.63M	0.02%	571

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Integral Derivatives's GSK Position: Q2 2017 in Review

Integral Derivatives sold out of GSK (GSK) in Q2 2017, closing a stake of 6,539 shares — an estimated $349K sold.

Integral Derivatives first reported a position in GSK in Q4 2013 and held it in 7 quarters. The position peaked at $1.68M in Q4 2013. 780 funds tracked by Wall St. Rank hold GSK as of Q2 2017.

Integral Derivatives reported no remaining GSK position as of Q2 2017 after selling out during the quarter.
Integral Derivatives sold 6,539 GSK shares in Q2 2017, an estimated $349K.
Integral Derivatives first reported a position in GSK in Q4 2013 and held it in 7 quarters.
Integral Derivatives's GSK position peaked at $1.68M in Q4 2013.
780 funds tracked by Wall St. Rank held GSK as of Q2 2017.

Based on Integral Derivatives's 13F filing for Q2 2017, filed 14 Aug 2017.